2012-2017年辽宁地区城市居民肺癌筛查结果分析

目的 分析2012-2017年辽宁省城市癌症早诊早治项目肺癌筛查结果,评价癌症早诊早治对居民预防肺癌的意义。方法 于2012-2017年,采用整群抽样方法对辽宁地区城市中40~74岁居民进行防癌风险问卷调查,对评估为肺癌高风险人群进行低剂量螺旋CT 扫描。采用x2检验方法比较组间高风险率、筛查率及检出率差异。结果 共收集人群调查问卷200249份,评估为肺癌高风险者39669人,高风险率为19.81%。高风险者中实际完成低剂量螺旋CT 检查13133人,筛查率为33.11%,女性筛查率（39.63%）高于男性（27.07%）（x2=705.967,P＜0.001）,50~59岁年龄组筛查率最高（34.03%）（x2=11.339,P＜0.001）。检出肺内结节1062人,检出率为8.09%,随着年龄增长肺内阳性结节检出率增高,差异有统计学意义（x2=46.499,P＜0.001）;检出疑似肺癌病人75例,检出率为0.57%,且随着年龄增加而增加,40~49岁组,50~59岁组,60~69岁组,70~74岁组检出率分别为0.25%、0.40%、0.95%和3.47%,差异有统计学意义（x2=40.261,P＜0.001）。结论 辽宁城市地区肺癌筛查参与率较低,肺内结节及可疑肺癌检出率较低。     

芜湖市社区居民脂肪肝患病现状及影响因素分析

目的 通过了解芜湖市城市社区居民的脂肪肝的患病情况以及相关影响因素,为早期合理的预防控制提供理论依据。方法 整群抽取芜湖市某个社区的18岁以上常住居民作为研究对象,开展健康体检和流行病学调查。结果 共901例研究对象参与调查,脂肪肝检出率为18.31%,其中男性检出率（29.0%）高于女性（5.6%）,差异具有统计学意义（χ2=82.24,P<0.001）;脂肪肝检出率有随年龄增高而增高的趋势（χ_趋势2=24.44, P<0.001）,以50~岁年龄组检出率最高（31.0%）。脂肪肝组血脂异常率（57.3%）高于非脂肪肝组（11.8%）,差异具有统计学意义 （χ2=163.46,P<0.001）。Logistic回归结果显示:性别（OR=2.475,95% CI:1.344~4.545）、年龄（OR=1.030, 95% CI:1.008~1.053）、体质指数（OR=1.584,95% CI:1.434~1.750）、总胆固醇水平（OR=2.134, 95% CI:1.340~3.398）、高密度脂蛋白胆固醇水平（OR=0.064, 95% CI:0.020~0.199）是脂肪肝发生的影响因素。结论 芜湖市社区居民脂肪肝患病情况不容乐观,应予以重视并针对其危险因素开展健康教育和重点防控。     

农村地区高危人群胃癌肝癌筛查效果评估

目的评估农村地区高危人群胃癌、肝癌筛查效果,为相关疾病防治提供依据。方法对适宜年龄段人群（胃癌40~69岁,肝癌35~64岁）开展癌症相关危险因素问卷调查,并按高危人群判定标准,筛选出符合筛查条件的高危人群,经知情同意后,进入临床筛查（胃癌：腔镜＋病理,肝癌：AFP＋B超）。结果检出胃癌4例（0.16%）（其中早期胃癌3例）、癌前病变（异型增生）55例（2.26%）;检出肝癌7例（占0.25%）（其中早期肝癌2例）,肝硬化23例（占0.83%）,AFP异常（≥10μg/L）126例（占9.6%）;检出其他肝脏异常者369人（占12.2%）。肝癌和肝硬化病例中HBsAg阳性比例较高,分别为85.7%（6/7）和82.6%（19/23）。结论定点、定人群、定期开展两癌筛查是发现早期病例的重要手段,同时,应普及防癌知识和提高基层医务人员对早期癌症的识别能力,以提高机会性发现早期癌症的比例。     

衢州市农村居民脂肪肝的超声诊断及相关因素分析

目的：了解衢州市农民脂肪肝患病情况,分析其致病相关因素。方法：结合新型农村合作医疗健康体检工程,随机抽取郊区和山区农村健康体检人员通过腹部超声筛查脂肪肝患者,抽取静脉血作代谢生化指标检测,并对脂肪肝形成相关因素进行分析。结果：脂肪肝的超声检出率为8.20%（1615/18 070）,其中郊区组检出率12.49%,山区组检出率5.48%,两组差异有统计学意义（P〈0.01）。郊区组检出率男性（11.68%）低于女性（13.12%）,男性检出率最高的是60~69岁年龄段,女性最高的是50~59岁年龄段;山区组检出率男性（6.64%）高于女性（4.51%）;郊区组各年龄段的脂肪肝检出率均高于山区组;单因素与多因素Log istic回归分析,脂肪肝形成的共同因素是肥胖、胆石症、高甘油三酯血症、糖尿病和高血压。结论：郊区农村已是脂肪肝等代谢性疾病的高发区,要重点加强郊区农村人群代谢性疾病监测管理和健康宣传教育。     

2012—2020年三亚市老年人非酒精性脂肪肝患病趋势及影响因素分析

目的 了解三亚市纳入基本公共卫生服务均等化健康管理的老年人非酒精性脂肪肝患病趋势及其影响因素,为防治提供依据。方法 对2012—2020年在三亚市基层医疗机构参加健康管理并进行B超检测的老年人信息进行分析。采用多因素logistic回归分析影响脂肪肝患病的相关因素。结果 2012—2020年三亚市纳入健康管理的老年人脂肪肝患病率从14.31%上升至23.78%,呈线性上升趋势（P<0.001）,年均增长率为6.55%。2012—2020年,城市与农村老年人脂肪肝患病率均呈线性增长趋势(P＜0.001),年均增长率分别为10.37%与3.67%,城市患病率均高于农村（P<0.01）。男性与女性脂肪肝患病率均呈线性增长趋势(P＜0.001),年均增长率分别为5.46%与7.14%,除2012年外,女性患病率均高于男性（P<0.01）。除85岁及以上老年人外,65～69岁、70～74岁、75～79岁、80～84岁老年人脂肪肝患病率均呈线性增长趋势（P＜0.001）,年均增长率分别为6.56%、6.50%、7.30%和7.24%。多因素logistic回归分析显示,超重/肥胖（OR=2.918）、TG升高（OR=2.410）、城市居住（OR=2.033）、腹型肥胖（OR=1.832）、空腹血糖受损（OR=1.291）、糖尿病（OR=1.793）、女性（OR=1.467）与脂肪肝患病有关。结论 2012—2020年三亚市健康管理老年人脂肪肝增长较快,防控形势严峻。需对女性、城市、低年龄组等脂肪肝高发人群进行重点干预,加强健康教育与健康促进,对与脂肪肝患病升高有关的因素进行针对性干预,以降低脂肪肝患病率,降低脂肪肝危害。     

事业单位人员脂肪肝患病情况及与体重指数、血脂水平的关系

目的了解事业单位人员的脂肪肝患病情况及与体重指数(BMI)、血脂水平的关系,为改善事业单位人员健康状况提供依据。方法以2008年参加体检的部分事业单位人员813名为研究对象,对其进行脂肪肝检查,身高、体重测量和血脂检测,分析事业单位人员脂肪肝患病情况,及其与BMI、血脂水平的关系。结果肪事业单位人员脂肪肝检出率男性为59.09%、女性为39.41%;19~45岁年龄组脂肪肝检出率为26.02%,46~59岁年龄组为58.01%,≥60岁年龄组为49.67%,各年龄组脂肪肝检出率男性均高于女性。脂肪肝患病组BMI、血清甘油三酯水平分别为(27.08±3.11)kg/m2、(2.14±1.26)mmol/L,与非脂肝组的(22.19±3.02)kg/m2、(1.60±0.81)mmol/L比较,差别有统计学意义(P<0.01)。结论事业单位人员脂肪肝患病率较高,且患病人群的体重和甘油三酯水平较高。     

2013—2018年安徽省淮河流域肝癌早诊早治项目高危人群肝癌检出率及相关因素分析

目的 了解2013—2018年安徽省淮河流域肝癌早诊早治项目高危人群肝癌检出率及相关因素。方法 于2013—2018年,在安徽省淮河流域6个区(县)采用整群抽样的方法选取当地乡或村中35～64岁常住居民,通过健康因素调查问卷和乙肝表面抗原检测评估出肝癌高危人群。其中34 957名居民参与了后续腹部B超检查和血清甲胎蛋白检测联合筛查。采用χ²检验和logistic回归模型分析肝癌检出率的相关因素。结果 在34 957名肝癌筛查参与者中,共检出肝癌182例,检出率为0.52%。多因素回归模型显示：女性(OR=0.435,95%CI:0.307～0.616)、35～40岁组(OR=0.135,95%CI:0.032～0.561)、41～50岁组(OR=0.618,95%CI:0.413～0.925)、超重(OR=0.712,95%CI:0.522～0.973)和肥胖(OR=0.390,95%CI:0.207～0.735)的人群肝癌检出率更低;与未患肝硬化和HBsAg检测阴性组相比,仅有肝硬化(OR=7.250,95%CI:5.142～10.221)、仅HBsAg检测阳性...     

七项检测指标对肝硬化及肝癌的诊断价值

目的探讨血清丙氨酸转氨酶(ALT),碱性磷酸酶(ALP),总胆红素(T-BIL),总蛋白(TP),白蛋白(ALB)5项生化指标及血清甲胎蛋白(AFP),HBsAg检测对肝硬化及肝癌的诊断和鉴别诊断价值.方法对57例肝硬化患者和43例肝癌患者血清用美国魅力2000型全自动生化分析仪检测生化5项及酶联免疫吸附试验(ELISA)法检测AFP,HBsAg,并检测结果进行分析.结果57例肝硬化标本异常率为T-BIL 73.7%;TP、ALB 64.9%;ALT、ALP 57.9%;HBsAg、AFP阳性率分别为33.3%和7.0%.43例肝癌标本异常率为ALP 90.7%;ALT 53.5%;T-BIL 48.2%;TP、ALB 37.2%.AFP、HBsAg阳性率分别为97.7%和74.4%.结论AFP,ALP对肝癌病例具有较高的灵敏度和特异性;7项检测指标对肝癌与肝硬化病例具有诊断与鉴别诊断价值.     

宝应县某企业职工“三高”及脂肪肝现状分析

目的了解宝应县企业普通职工"三高"(血压、高血糖、高血脂)及脂肪肝患病情况。方法在参加2010年宝应县职业健康体检企业职工,随机抽取年龄19～59周岁职工进行生化检验,共调查261名。结果该人群"三高"及脂肪肝检出率为41.8%(109/261),各年龄组检出率男性明显高于同年龄组女性,同性别不同年龄组之间检出率无统计学差异;≥35周岁年龄组中男性高血压检出率明显高于女性;不同年龄组中男性高脂血症检出率明显高于同年龄组女性,≥35周岁年龄组高脂血症检出率明显高于同性别<35周岁年龄组人员;各年龄组男性脂肪肝检出率明显高于同年龄组女性;男性中35岁以上年龄组检出3种以上问题的比例明显高于35岁以下年龄组的男性及同年龄组的女性。结论宝应地区企业男性职工高血压、高血脂、脂肪肝检出率较高,尤其是35岁以上的男性职工。应加强对企业普通职工"三高"及脂肪肝的防治工作。     

河南省某三甲医院1 500名健康体检人群结肠镜检查结果

目的 分析郑州市健康体检人群结肠镜检查结果。方法 选取2019年在郑州大学第一附属医院健康管理中心接受健康体检（含结肠镜检查）者1 500名,对其结肠镜检查结果进行回顾性分析。结果 总体病变检出845例,检出率56.33%,以结直肠息肉检出率最高（42.80%）。男性结直肠息肉、结直肠慢性炎症、结直肠憩室检出率高于女性,女性结肠黑变病检出率高于男性（P<0.05）。结直肠息肉发病部位主要集中于直肠、乙状结肠、横结肠、降结肠,且这些部位男性检出率均高于女性（P<0.05）。40～69岁男性结直肠息肉检出率高于女性（P<0.05）。646例进行病理检查,检出腺瘤259例（40.09%）,主要为管状腺瘤189例（29.26%）。60～69岁男性腺瘤的检出率高于女性（P<0.05）。结论 郑州市≥40岁健康体检人群存在较高的结直肠息肉与腺瘤检出率风险,是结直肠癌筛查的重要目标人群。     

Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan

BACKGROUND: There is a tendency for familial aggregation of hepatocellular carcinoma (HCC). The aims of this study were to assess the degree to which familial aggregation of hepatitis B surface antigen (HBsAg) carriers accounts for familiality of HCC in families of hepatitis B-related HCC patients, and whether HCC shares a familial predisposition with liver cirrhosis among HBsAg carriers. METHODS: A total of 671 first-degree relatives of HBsAg-positive HCC cases were recruited using abdominal ultrasonography and tests for HBsAg and serum aminotransferases. They were from 165 simplex families defined as having only one HCC case and 72 multiplex families with more than one case. In analyses of family history of HCC and cirrhosis, the data set consisted of 4,471 unrelated asymptomatic HBsAg carriers recruited in a prospective study. RESULTS: There was no significant difference in the HBsAg-positive rate among relatives between multiplex (55.7%) and simplex (48.1%) families. Sonographic evidence of liver cirrhosis was present in 14.4% of HBsAg-positive relatives from multiplex families but in only 7.8% of HBsAg-positive relatives from simplex families (multiplex versus simplex families: adjusted odds ratio [OR] = 2.29; 95% CI: 1.10-4.77). Among unrelated asymptomatic HBsAg carriers, the adjusted OR of liver cirrhosis associated with a first-degree family history of HCC was 2.80 (95% CI: 1.68-4.66). This association was stronger in HBsAg carriers <50 years. No association was seen between family history of HCC and hepatitis activity based on elevated levels of aminotransferases. CONCLUSIONS: Familial aggregation of HCC in HBsAg carriers is associated with familial clustering of liver cirrhosis.     

肝癌组织、癌旁组织中HBsAg、HCV抗原表达与肝组织纤维化分期的相关性研究

目的研究肝癌组织、癌旁组织中乙型肝炎表面抗原（HBsAg）、丙型肝炎病毒（HCV）抗原表达与肝组织纤维化分期的相关性.方法采用免疫组织化学方法对肝癌组织及癌旁组织中的HBsAg、HCV抗原表达进行了标记和分析,同时对肝癌组织及癌旁组织进行肝组织纤维化分期.结果肝组织纤维化程度与HBV、HCV感染有明显相关性（rs=0.32,P=0.001）;HBsAg和HCV抗原在癌组织及癌旁组织中表达有差异,HBsAg主要在癌旁组织表达（79%）,高于癌组织（23%）;而HCV抗原在癌组织（15%）与癌旁组织表达（23%）水平相当.结论有病毒感染背景的肝癌组织,其纤维化程度高于无病毒感染的肝癌组织;病毒的感染是肝癌发生的原因,长期的病毒血症会加速肝纤维化的进展.     

青年及老年原发性肝癌的比较分析

目的：探讨青年及老年人原发性肝癌的临床特点。方法：对95例年龄≤39岁的青年肝癌和112例年龄≥60岁的老年肝癌患者进行临床分析。结果：（1）青年组HBVM感染率为92．63％，其HBsAg( )为84．21％，明显高于老年组的62．50％。（P＜0．01）（2）青年组合并肝硬化者达72．63％，高于老年组的54．46％。（P＜0．01）（3）青年组肝区疼痛症状明显高于老年组，青年组以弥散型和巨块型多见，而老年组则以单个局限为主。（4）青年组AFP（＋）为67．37％，青年组为46．43％（P＜0．05）（5）老年组AKP、r-GT明显高于青年组，心脑血管合并症亦多于青年组（P＜0．01）。结论：青年肝硬化患者是原发性肝癌最重要的高危因素。应对这些患者长期追踪观察以及早发现和诊断肝癌。老年肝病患者AFP阳性率低，当其出现AKP、r-GT值升高时，应高度警惕。     

Endemic hepatitis B virus infection and chronic liver disease mortality in the Republic of Palau, 1990-2002

In the Republic of Palau, a Pacific island nation, approximately 20% of the population is chronically infected with hepatitis B virus (HBV) and is at risk of developing chronic liver disease (CLD), including cirrhosis and hepatocellular carcinoma (HCC). To examine the consequences of HBV infection, we sought to quantify HBV-related CLD mortality in this population. The cause of death was abstracted from death certificates of all persons who died in Palau during 1990-2002. CLD deaths were categorised as cirrhosis or HCC. HBV serological status was determined by review of a hospital database. The cause of death was determined for 1,366 (85%) of 1,608 deaths. CLD was the fifth most common cause of death, accounting for 102 (7%) deaths with a known cause. Of deaths due to CLD, 55 (54%) were from cirrhosis and 47 (46%) were from HCC. Sixty-five percent of CLD decedents and 19% of non-CLD decedents were chronically infected with HBV (P<0.01). The attributable fraction of HBV-related CLD was 54% (58% for cirrhosis and 53% for HCC). CLD mortality rates were approximately twice the worldwide CLD rate. HBV-related CLD is a common cause of death in the Republic of Palau, highlighting the importance of routine infant hepatitis B vaccination, especially in countries with high endemicity.     

2013-2018年浙江省城市癌症早诊早治项目人群肝癌筛查结果及相关因素分析

目的分析2013-2018年浙江省城市癌症早诊早治项目人群肝癌筛查结果及相关因素。方法于2013年9月至2019年8月,以浙江省杭州(江干区和拱墅区)、宁波(海曙区、鄞州区和江北区)和衢州市(柯城区)的6个城市社区为研究现场,采用整群抽样方法,选取所有年龄为40~74岁的常住居民(具有本地户籍且在本地居住3年以上)为研究对象,排除已确诊肿瘤患者、罹患其他严重内外科疾病正在治疗的患者后,共纳入166293名研究对象。通过问卷调查收集研究对象的基本人口学特征和危险因素等信息,采用癌症风险评估系统评价研究对象的肝癌患病风险,同时从项目参与医院获取肝癌高危人群的临床筛查参与情况和筛查结果,计算肝癌高危率、临床筛查率、阳性病变检出率及疑似肝癌检出率等结果,并采用Poisson回归模型分析肝癌检出的相关因素。结果166293名研究对象年龄为(56.01±8.40)岁,其中男性占41.36%(68777名)。共筛出23765名肝癌高危人群(高危率为14.29%);其中,共有12375名对象参加了肝癌临床筛查,筛查率为52.07%(12375/23765);共检出297例阳性病变,检出率为2.40%(297/12375);其中检出8例疑似肝癌,检出率为0.06%(8/12375)。多因素Poisson回归模型分析结果显示,与男性、从不吸烟、从不食用腌晒食品、食用油脂含量不高、无肝胆系统疾病史的人群相比,女性、正在吸烟/曾经吸烟、有时食用腌晒食品、食用油脂含量较高、有肝胆系统疾病史人群的阳性病变检出率更高,发生率比(IRR)(95%CI)值分别为1.98(1.45~2.70)、2.23(1.61~3.09)/2.08(1.31~3.28)、1.82(1.22~2.70)、1.44(1.08~1.91)、1.45(1.05~2.00);与40~49岁、未做过HBsAg检测相比,70~74岁、HBsAg阳性人群的疑似肝癌检出率更高,IRR(95%CI)值分别为16.30(1.32~200.74)、6.43(1.24~33.22)。结论浙江省城市癌症早诊早治项目肝癌临床筛查依从性较好,在肝癌高危人群中进行腹部超声检查和血清甲胎蛋白检测有助于发现肝癌及其癌前病变。     

Mortality of hepatitis B surface antigen-positive blood donors in England and Wales

BACKGROUND: Large population-based cohort studies in areas of high hepatitis B virus (HBV) prevalence have provided the evidence establishing hepatitis B surface antigen (HBsAg) carriage as a risk factor for hepatocellular carcinoma (HCC) and liver disease. Fewer studies have examined this in Western countries, where both HBV infection and carriage are less common and transmission patterns differ. This is the only prospective population-based study to examine this relationship in Europe. METHODS: In all, 2681 male and 977 female blood donors in England and Wales, found to be HBsAg positive during routine blood-donation screening, were followed up from recruitment in 1970-1982 to December 1999 and their cause-specific mortality was analysed. This was compared with that of the general population of England and Wales. RESULTS: During a mean of 22 years of follow-up, 17.4% of the 420 deaths were due to HCC or liver disease. There were 20 deaths from HCC in male HBsAg carriers, representing a significantly high standardized mortality ratio (SMR) compared to the male population of England and Wales of 26 (SMR = 26.26; 95% CI: 16.04- 40.54). The HCC incidence rate in males was 33.5 per 100 000 person years and 4.4 per 100 000 person years in females. Men had 8.5 (SMR = 8.50; 95% CI: 6.25- 11.31) and women had 3.9 times the risk of death from liver disease (SMR = 3.89; 95% CI: 1.26-9.09). The risk of circulatory disease deaths was reduced in both males and females. There was a significant increased risk of non-Hodgkins lymphoma that was not apparent in the first decade of follow-up. The increased risk of HCC and liver disease in men fell with follow-up. CONCLUSION: Hepatitis B surface antigen carriage is a significant risk factor in England and Wales for both liver disease and HCC mortality. However, this risk has declined with duration of follow-up. This could be due to natural reversion to HBsAg negativity or as a result of treatment and avoidance of other risk factors. The increased risk of non-Hodgkins lymphoma seen in longer follow-up is likely to be related to HIV infection acquired subsequent to recruitment.     

Hepatitis B and primary cancer of the liver in intertropical Africa

During the past 15 years, a growing body of evidence incriminates hepatitis B virus as the major factor in the etiology of primary liver cancer. Epidemiological studies throughout the world reported a striking correspondence between areas where the frequency of primary liver cancer is high and where HBV infection is hyperendemic. Moreover, primary liver cancer is commonly associated with cirrhosis of the postnecrotic macronodular type. Such data suggested a sequence hepatitis-cirrhosis-PLC. Such sequence was confirmed by extensive serologic testing studies which reported a high frequency of HBV markers in PLC patients compared to matched control groups. Data collected in Senegal, Mali and Burundi on 12,000 individuals stress the importance of HBV infections in these countries, as the high rate of chronic carrier state in patients suffering from liver cirrhosis or primary liver cancer (62-63%) compared to the general population (12-17%). Other HBV markers including anti-HBs, anti-HBc, HBeAg and anti-HBe had no prognostic value in the sequence hepatitis-cirrhosis-PLC. A new HBV seric marker, the HBsAg/IgM complexes, observed in HBsAg positive individuals, is more frequently detected in PLC patients (50%) and cirrhosis (40%) than in healthy HBsAg carriers (14%). These results would indicate that HBsAg carriers are more likely to develop cirrhosis or primary liver cancer when they evidence HBsAg/IgM complexes. In conclusion, the seric markers of evolution towards primary liver cancer are: HBsAg (the highest known risk factor), the presence in such individuals of HBsAg/IgM complexes, and increased values of alphafoetoprotein.     

肝癌端粒酶逆转录酶表达与端粒酶活性相关性及临床意义

目的 探讨肝细胞肝癌（HCC）中端粒酶逆转录酶（hTERT）蛋白表达情况与端粒酶活性的相关性及其临床意义。方法 采用免疫组化S-P法检测52例HCC癌组织及相应癌旁组织中hTERT蛋白表达，并用TRAP-ELISA法检测上述组织中的端粒酶活性。结果 HCC癌组织中hTERT蛋白与端粒酶活性表达阳性率分别为86．5％（45／52）和80．8％（42／52），它们与相应癌旁组织比较差异均有显著性（P〈0．01）；且癌组织中hTERT蛋白阳性表达与端粒酶活性呈高度正相关（r=0．761，P〈0．001）。hTERT蛋白阳性表达与患者的性别、年龄、有无乙肝、肝硬化、肝功能、肿瘤包膜、病理分级及分期等临床指标无关，而与HCC肿瘤大小有关（P〈0.05）。结论 HCC癌组织中hTERT蛋白过度表达，可能参与肝癌端粒酶活性的调控，而在HCC发生、发展中起重要作用。hTERT蛋白表达与端粒酶活性均可作为HCC诊断的特异性指标。     

Hepatitis B carriage explains the excess rate of hepatocellular carcinoma for Maori, Pacific Island and Asian people compared to Europeans in New Zealand.

BACKGROUND: The aim of this research was to determine the hepatitis B surface antigen (HBsAg) carrier prevalence among cases of hepatocellular carcinoma (HCC), and the population attributable risk of HBsAg carriage for HCC, by ethnicity in New Zealand. METHODS: The hospital notes of HCC cases registered with the New Zealand Cancer Registry, for the years 1987-1994 inclusive, were viewed to determine the HBsAg status. Results The HBsAg status was determined for 193 cases of HCC. The HBsAg carrier prevalence for non-Europeans with HCC was markedly higher than that for Europeans, being 76.7% for Maori, 80.0% for Pacific Island people, and 88.5% for Asians, compared to 6.0% for Europeans. In addition to the effect of ethnicity, HCC cases aged <60 years were more likely to be HBsAg carriers than those aged > or = 60 years. The estimated population attributable risk of HBsAg for HCC, within each ethnic group, was only marginally less than the HBsAg prevalence due to the high relative risk of HBsAg carriage for HCC. The standardized incidence rate ratios of HCC for Maori, Pacific Island people and Asians compared to Europeans were 9.6, 20.4, and 22.3, respectively. Hepatocellular carcinoma attributable to HBsAg carriage explained 79%, 83%, and 92% of the excess standardized rate of HCC, compared to Europeans, for Maori, Pacific Island people, and Asians, respectively. Conclusions The HBsAg carrier prevalence in non-European cases of HCC in New Zealand is between 75% and 90%. HBsAg carriage explains the majority of the excess rate of HCC in non-Europeans compared to Europeans in New Zealand.